组织中DcR3的表达对上皮性卵巢癌患者病理分型、临床分期与预后的影响

The effect of expression of DcR3 on the clinicopathological characteristics and prognosis of epithelial ovarian cancer

目的:探讨组织中诱骗受体3(DcR3)的表达对上皮性卵巢癌患者病理分型、临床分期与预后的影响。方法:选取2013年1月至2015年1月新疆医科大学附属肿瘤医院收治的66例上皮性卵巢癌患者和60例良性卵巢肿瘤患者作为研究对象。采用免疫组织化学SP法检测良性卵巢肿瘤患者和上皮性卵巢癌患者体内DcR3的表达水平及其阳性表达率。比较上皮性卵巢癌患者中Ⅰ~Ⅱ期与Ⅲ~Ⅳ期、高分化与低分化、淋巴转移与无淋巴转移患者的DcR3阳性表达率情况,并比较DcR3阳性表达患者与DcR3阴性表达患者的中位生存期。结果:上皮性卵巢癌患者的DcR3阳性表达率明显高于良性卵巢肿瘤患者(P<0.05);上皮性卵巢癌患者中,Ⅰ~Ⅱ期患者的DcR3阳性表达率高于Ⅲ~Ⅳ期患者(P<0.05),高分化患者DcR3阳性表达率高于低分化患者(P<0.05),有淋巴转移患者阳性表达率DcR3高于无淋巴转移患者(P<0.05)。DcR3阳性表达组患者的中位生存期明显短于DcR3阴性表达组患者(P<0.05)。结论:上皮卵巢癌患者组织中DcR3的阳性表达率越高,其病理分型、临床分期越高,淋巴转移的风险也越高,且患者的中位生存期越短。

Objective： To investigate the effect of the expression of decoy receptor 3 （DcR3） on the patho logical classification, clinical stage and prognosis of patients with epithelial ovarian cancer. Methods： from January 2013 to January 2015, 66 patients with epithelial ovarian cancer and 60 patients with benign ovarian tumor were selected as the subjects. The expression of DcR3 and the positive expression rate in patients with benign ovarian tumor and epithelial ovarian cancer were detected by immunohistochemistry. The DcR3 positive rate was compared between patients with epithelial ovarian cancer in stage Ⅰ- Ⅱ and Ⅲ-Ⅳ, high differentiation group and low differentiation group, lymph node metastasis and without lymph node metastasis. The median survival was compared between DcR3 positive and negative expression patients. Results： The positive expression rate of DcR3 in epithelial ovarian cancer patients was significantly higher than that in patients with benign ovarian tumor （P〈0.05）. In patients with epithelial ovarian cancer, the positive rate of stage Ⅰ- Ⅱ patients was higher than that of patients with stage Ⅲ-Ⅳ （P〈0.05）, the positive rate of high differentiation group was higher than that of low differentiation group （P〈0. 05）. The positive rate of patients with lymph node metastases was higher than that of patients without lymph node metastasis （P〈0.05）. The median survival time of DcR3 positive patients was significantly longer than that of DcR3 negative patients （P〈0.05）. Conclusion： The higher positive expression rate of DcR3 in epithelial ovarian cancer patients was related to higher pathological type and clinical stage, the higher risk of lymphatic metastasis, and the shorter the median survival time.